Comparative Pharmacology
Head-to-head clinical analysis: TRIPLE SULFA versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPLE SULFA versus TRYSUL.
TRIPLE SULFA vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic